-
公开(公告)号：US09051567B2
公开(公告)日：2015-06-09
申请号：US13378346
申请日：2010-06-15
IPC分类号： A61K31/713 , A61K9/127 , A61P3/06 , C12N15/11 , C12N15/113 , C12N9/64
CPC分类号： C12N15/113 , A61K9/127 , A61K31/366 , A61K31/567 , A61K31/7088 , C12N9/6454 , C12N15/111 , C12N15/1135 , C12N15/1136 , C12N15/1137 , C12N15/1138 , C12N2310/14 , C12N2320/31 , C12N2320/32 , C12Y304/21061
摘要： This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that increases LDL receptor levels.
摘要翻译： 本发明涉及通过预先施用增加LDL受体水平的试剂来提高siRNA施用效率的方法。
-
公开(公告)号：US20120244207A1
公开(公告)日：2012-09-27
申请号：US13378346
申请日：2010-06-15
IPC分类号： A61K31/713 , A61P3/06 , A61K9/127
CPC分类号： C12N15/113 , A61K9/127 , A61K31/366 , A61K31/567 , A61K31/7088 , C12N9/6454 , C12N15/111 , C12N15/1135 , C12N15/1136 , C12N15/1137 , C12N15/1138 , C12N2310/14 , C12N2320/31 , C12N2320/32 , C12Y304/21061
摘要： This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.
摘要翻译： 本发明涉及通过预先施用降低LDL受体水平的试剂来提高siRNA施用效率的方法。
-
公开(公告)号：US20110230542A1
公开(公告)日：2011-09-22
申请号：US12554231
申请日：2009-09-04
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
IPC分类号： A61K31/713 , C12N5/00 , C07H21/02 , A61P3/06
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and
摘要翻译： 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 并且其与PCSK9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由PCSK9基因表达引起的疾病和PCSK9基因表达的方法; 和
-
4.发明授权公开(公告)号：US08222222B2
公开(公告)日：2012-07-17
申请号：US12554231
申请日：2009-09-04
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and methods for inhibiting expression of a PCSK9 gene in a cell.
摘要翻译： 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 并且其与PCSK9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由PCSK9基因表达引起的疾病和PCSK9基因表达的方法; 以及抑制细胞中PCSK9基因表达的方法。
-
公开(公告)号：US20130331430A1
公开(公告)日：2013-12-12
申请号：US13472438
申请日：2012-05-15
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
IPC分类号： C12N15/113
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and
摘要翻译： 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 并且其与PCSK9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由PCSK9基因表达引起的疾病和PCSK9基因表达的方法; 和
-
6.发明授权公开(公告)号：US08809292B2
公开(公告)日：2014-08-19
申请号：US13472438
申请日：2012-05-15
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
摘要翻译： 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 并且其与PCSK9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA以及药学上可接受的载体的药物组合物和用于治疗由PCSK9基因表达引起的疾病的方法。
-
7.发明授权公开(公告)号：US07605251B2
公开(公告)日：2009-10-20
申请号：US11746864
申请日：2007-05-10
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; and methods for treating diseases caused by PCSK9 gene expression by using the pharmaceutical composition.
摘要翻译： 本发明涉及用于抑制前蛋白转化酶枯草杆菌蛋白酶kexin 9（PCSK9）基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，通常为19-25 核苷酸长度，并且其与PCSK9基因的至少一部分基本互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 以及通过使用该药物组合物治疗由PCSK9基因表达引起的疾病的方法。
-
公开(公告)号：US20080113930A1
公开(公告)日：2008-05-15
申请号：US11746864
申请日：2007-05-10
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor Kotelianski
IPC分类号： C07H21/02 , A61K31/7115 , C12N15/00 , C12N5/10
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and
摘要翻译： 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含具有长度小于30个核苷酸的核苷酸序列的反义链，通常为19-25个核苷酸 并且其与PCSK 9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由PCSK9基因表达引起的疾病和PCSK 9基因的表达的方法; 和
-
9.发明授权Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression 有权抑制铁调素抗菌肽（HAMP）或HAMP相关基因表达的组合物和方法公开(公告)号：US09228188B2
公开(公告)日：2016-01-05
申请号：US14118489
申请日：2012-06-21
申请人： Brian Bettencourt , Akin Akinc , Alfica Sehgal , Don Foster , Stuart Milstein , Satyanarayana Kuchimanchi , Martin A. Maier , Klaus Charisse , Kallanthottathil Rajeev
发明人： Brian Bettencourt , Akin Akinc , Alfica Sehgal , Don Foster , Stuart Milstein , Satyanarayana Kuchimanchi , Martin A. Maier , Klaus Charisse , Kallanthottathil Rajeev
IPC分类号： C12N15/11 , C12N15/113 , A61K31/7105 , A61K33/26 , A61K47/48
CPC分类号： C12N15/113 , A61K31/7105 , A61K33/26 , A61K47/48092 , A61K47/549 , C12N15/1136 , C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/351 , C12N2310/3515 , C12N2310/3521 , C12N2310/3533 , C12N2320/30
摘要： The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) targeting a hepcidin antimicrobial peptide (HAMP) and/or HAMP-related gene, and methods of using the dsRNA to inhibit expression of HAMP and/or HAMP-related genes.
摘要翻译： 本发明涉及靶向铁调素抗体肽（HAMP）和/或HAMP相关基因的脂质配制双链核糖核酸（dsRNA），以及使用dsRNA抑制HAMP和/或HAMP相关基因表达的方法。
-
10.发明申请Compositions and Method for Inhibiting Hepcidin Antimicrobial Peptide (HAMP) or HAMP-Related Gene Expression 有权抑制Hepcidin抗菌肽（HAMP）或HAMP相关基因表达的组合物和方法公开(公告)号：US20140127325A1
公开(公告)日：2014-05-08
申请号：US14118489
申请日：2012-06-21
申请人： Brian Bettencourt , Akin Akinc , Alfica Sehgal , Don Foster , Stuart Milstein , Satyanarayana Kuchimanchi , Martin A. Maier , Klaus Charisse , Kallanthottathil Rajeev
发明人： Brian Bettencourt , Akin Akinc , Alfica Sehgal , Don Foster , Stuart Milstein , Satyanarayana Kuchimanchi , Martin A. Maier , Klaus Charisse , Kallanthottathil Rajeev
IPC分类号： C12N15/113 , A61K47/48 , A61K33/26 , A61K31/7105
CPC分类号： C12N15/113 , A61K31/7105 , A61K33/26 , A61K47/48092 , A61K47/549 , C12N15/1136 , C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/351 , C12N2310/3515 , C12N2310/3521 , C12N2310/3533 , C12N2320/30
摘要： The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) targeting a hepcidin antimicrobial peptide (HAMP) and/or HAMP-related gene, and methods of using the dsRNA to inhibit expression of HAMP and/or HAMP-related genes.
摘要翻译： 本发明涉及靶向铁调素抗体肽（HAMP）和/或HAMP相关基因的脂质配制双链核糖核酸（dsRNA），以及使用dsRNA抑制HAMP和/或HAMP相关基因表达的方法。
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.033 秒)
